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therapeutic compounds that utilize this reductive bioac-
tivation pathway.
Introduction
Margarita Faig,1 Mario A. Bianchet,1 Shannon Winski,2
Robert Hargreaves,3 Christopher J. Moody,4
Anna R. Hudnott,4 David Ross,2 and L. Mario Amzel1,5
1 Department of Biophysics and Biophysical Chemistry
Johns Hopkins Medical School
Baltimore, Maryland 21205 NAD(P)H:Quinone acceptor oxidoreductase (EC
1.6.99.2; QR1 or NQO1; also called DT-diaphorase) is a2 School of Pharmacy and Cancer Center
University of Colorado Health Sciences Center flavoenzyme that catalyzes the obligatory two-electron
reduction of quinones to hydroquinones [1]. This reac-Denver, Colorado 80262
3 CRC Drug Development Group tion prevents the one-electron reduction of quinones by
cytochrome P450 reductase and other flavoproteins thatPatterson Institute for Cancer Research
Manchester, M20 4BX would result in oxidative cycling with generation of dele-
terious radical species. In addition to its role in the de-United Kingdom
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as thyroid, adrenal, breast, ovarian, colon, and non-
small-cell lung cancer (NSCLC) [2], this enzyme has be-
come an attractive target for enzyme-directed drug de-Summary
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Although the crystal structures of QR1 shed light onBackground: NAD(P)H:quinone acceptor oxidoreduc-
the enzyme mechanism [3, 4] and on the catalytic differ-tase (QR1) protects animal cells from the deleterious
ences among species [4, 5], until now only molecularand carcinogenic effects of quinones and other elec-
modeling has been used to obtain structural informa-trophiles. Remarkably, the same enzyme activates can-
tion about enzyme-prodrug interactions [6–8]. Most ofcer prodrugs that become cytotoxic only after two-elec-
these computer models have used information derivedtron reduction. QR1’s ability to bioactivate quinones and
from our crystal structures of rat enzyme complexesits elevated expression in many human solid tumors
with NADP and the ternary complex with DQ [2,3,5,6-makes this protein an excellent target for enzyme-
tetramethyl-1,4-benzoquinone] and CB (Cibacron Bluedirected drug development. Until now, structural analy-
3GA), a strong QR1 inhibitor [3]. Unfortunately, thesesis of the mode of binding of chemotherapeutic com-
structures are not good models for the binding of simplepounds to QR1 was based on model building using the
substrates, because in both cases the ligands extendstructures of complexes with simple substrates; no
well beyond the substrate binding site. Recently, westructure of complexes of QR1 with chemotherapeutic
reported the structures of the apo-hQR1 and the hQR1-prodrugs had been reported.
DQ complexes [4], but these new structures have not
yet been used in modeling studies. In any case, directResults: Here we report the high-resolution crystal
observation of the interaction of QR1 with chemothera-structures of complexes of QR1 with three chemo-
peutic prodrugs is necessary to understand sufficientlytherapeutic prodrugs: RH1, a water-soluble homolog of
their mode of binding in order to assist in the optimiza-dimethylaziridinylbenzoquinone; EO9, an aziridinylindo-
tion of this type of cytotoxic drug. In this paper, welequinone; and ARH019, another aziridinylindolequi-
report the crystal structures of complexes of recombi-none. The structures, determined to resolutions of 2.0 A˚,
nant human QR1 with a substituted aziridinylbenzoqui-2.5 A˚, and 1.86 A˚, respectively, were refined to R values
none and two aziridinylindolequinones, three drugs rep-below 21% with excellent geometry.
resenting two families of compounds that have been
used in clinical trials or are under preclinical develop-
Conclusions: The structures show that compounds can ment as potential QR1-directed antitumor agents.
bind to QR1 in more than one orientation. Surprisingly, Aziridinylbenzoquinones (AZQ; Figure 1) have under-
the two aziridinylindolequinones bind to the enzyme in gone clinical trials as potential antitumor agents [9]. Both
different orientations. The results presented here reveal one- and two-electron reduction of these compounds
two new factors that must be taken into account in the produces activated aziridine groups that can crosslink
design of prodrugs targeted for activation by QR1: the DNA strands [10, 11]. The activated drugs react with
enzyme binding site is highly plastic and changes to the N7 position of guanine in DNA, with a sequence
accommodate binding of different substrates, and ho- preference similar to that of other alkylating agents [12].
mologous drugs with different substituents may bind to Among these drugs, MeDZQ [2,5-diaziridinyl-3,6-methyl-1,
QR1 in different orientations. These structural insights 4-benzoquinone] (Figure 1 with X and X methyl group)
provide important clues for the optimization of chemo-
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resolution crystal structure of the hQR1 complex with
ARH019.
The crystal structures reported here are used to com-
pare the modes of binding of QR1 to the three chemo-
therapeutic drugs and to DQ, a simple acceptor sub-
strate [4]. This analysis provides valuable information
for the design of improved enzyme-directed chemother-
apeutic agents.
Results and Discussion
Structure Determination and Refinement
The crystal structures of complexes of human QR1 en-
zyme with three potential chemotherapeutic com-
pounds were determined and refined to R values lower
than 21% with excellent stereochemistry (Table 1). Each
structure has four copies of the hQR1-drug complex
(four molecules in the asymmetric unit). Final 2Fo  Fc
maps show excellent density for most portions of the
Figure 1. Drugs Used in the Present Study
polypeptide chains and for the four copies of the bound
Drug families are shown with R, R, X, and X indicating the positions
compounds (Figures 2a, 2b, and 2c). Ramachandranof substituents.
diagrams place over 87% of the residues in the most-
favored regions.
All 12 copies of the QR1 structure refined in thesehas been shown to be a good substrate for QR1, highly
crystals are highly similar, with some differences con-toxic in vitro for cell lines expressing high levels of the
centrated in the residues at one side of the active siteenzyme [13, 14]. MeDZQ also shows enhanced se-
over rings A and B of the flavin isoalloxazine. All four FADquence specificity after reduction [11]. However, low
molecules in each of the complexes show flat electronsolubility limits its use as a prodrug [11].
density for the isoallozaxine, indicating an oxidizedUsing MeDZQ as a lead compound, several new drugs
state. Alignments of 546  carbons of the apo humanwere synthesized in a second round of optimization that
dimer (Protein Data Bank accession code 1D4A) withincluded changes in size and electronic characteristics
each the three complexes yield root-mean-square devi-of substituents at positions 3 and 6 [11, 15]. RH1 [2,5-
ations (rmsd) in the range 0.26–0.34 A˚ (Table 1).diaziridinyl-3-hydroxyl-6-methyl-1,4-benzoquinone]
(Figure 1), one of the compounds utilized in the present
study, is an alkyl-substituted analog of MeDZQ that ex- Overall Structure of the Enzyme and Active Site
QR1 is a physiological homodimer made of two inter-hibits greater selective toxicity toward cells with elevated
QR1 activity than does the parent compound [15]. We also locked monomers of 273 residues related by a noncrys-
tallographic two-fold axis of symmetry. Each QR1 mono-report the crystal structures of two indolequinone drugs,
EO9 [3-hydroxymethyl-5-aziridinyl-1-methyl-2-(H-indole-4, mer is composed of two domains: a large catalytic
domain (residues 1–220) and a small C-terminal domain7-indione)-propenol] and ARH019 [3-hydroxymethyl-5-
(2-methylaziridin-1-yl)-1-methyl-2-phenylindole-4,7-dione], (residues 221–273). (Residue numbers in this paper are
those used in PDB, accession number 1D4A; they arein complex with QR1. These are members of a family of
antitumor agents structurally related to the commonly shifted down by one residue with respect to those in
some other publications.) The catalytic domain has anused drug mitomycin C (MC). EO9 (Figure 1), the better
known of these prodrugs, is reduced readily by rat QR1 / fold with flavodoxin topology. All three prodrugs
bind to the catalytic site of QR1 interacting with the(rQR1) but reduced 23 times slower by human QR1
(hQR1); it has a Km 5-fold higher than menadione [16–18]. bound FAD and with residues of both monomers. The
catalytic site (Figure 3), a 360 A˚3 pocket, alternately bindsNonetheless, EO9 is a better QR1 substrate than the
clinically proven MC, and it shows high toxicity in QR1- the nicotinamide portion of the NAD(P)H and the electron
acceptor substrate. This pocket is lined by residues fromrich cell lines [16]. Although partial responses in phase
I trials were promising, subsequent phase II trials in both monomers: Phe-178, Tyr-126, and Tyr-128 form
the roof of the active site; the isoalloxazine ring of FADcases that included NSCLC, breast, pancreatic, colo-
rectal, and gastric tumors were disappointing. This fail- makes up the floor; and His-161, the N-terminal of L6
(glycines 149 and 150), and two conserved water mole-ure has been attributed to poor delivery of EO9 to the
tumor and to its rapid plasma clearance. These results cules (W1 and W2) flank the cavity. (When referring to
the catalytic site, secondary structure elements and resi-motivated a search for drugs related to EO9 with better
pharmacodynamic characteristics. One such com- dues from individual monomers will be primed or un-
primed. As the two monomers are equivalent, primespound, ARH019 (Figure 1), was developed [19] by keep-
ing the important aziridinyl group at the indole position will be used only when distinction is needed.) In the
active site, a structural water molecule and three groups5 where it is essential for potency and selectivity [20],
but replacing the propenol group at the indole position of the protein—the hydroxyl groups of Tyr-126 and Tyr-
128 and the Nof His-161—are available to make hydro-2 with a phenyl group. Here, we also report a high-
Complexes of QR1 with Antitumor Prodrugs
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Table 1. Summary of the Crystallographic Analysis
Prodrug RH1 EO9 ARH019
Resolution 2.0 2.5 1.86
Unique reflections 77,600 38,859 94,724
Multiplicity 3.9 3.7 3.5
Completeness (last shell) 95.0 (83.8) % 81.7 (81.3) % 93.7 (84.0) %
Rsyma  100 9.1 8.4 7.3
Crystallographic Refinement
Number of reflections used 73,718 35,866 74,185
Number of model atoms 9,676 9,092 9,295
Number of ligand atoms 280 296 308
Number of solvent atoms 707 104 295
Rcryst/Rfree 19.9/25.6 19.9/27.9 20.9/25.7
Intensity cutoff 0.0 0.0 2.0
Rms bond/rms angles 0.008/1.3 0.008/1.39 0.008/1.37
Protein temperature factor (A˚2) 23.3 24.8 26.4
Ligands temperature factor (A˚2) 25.56 36.5 36.7
Solvent temperature factor (A˚2) 30.0 21.8 24.3
Surface buried apolar (A˚2) 447.0 492.0 584.5
polar (A˚2) 144.5 176.0 156.0
Occupancy factor 0.8 0.7 1.0
Drug temperature factor (A˚2) 38.5 26.0 56.0
Rms against Native dimer 0.22 (546) 0.23 (546) 0.20 (546)
(number of C atoms)
PDB ID code 1H66 1GG5 1H69
a Rsym  	h	j|Ihj  
Ih|/	h	j|Ihj|, where h represents a unique reflection and j means symmetry equivalent indices. I is the observed intensity
and 
I is the mean value of I.
gen bonds in the otherwise apolar pocket. As in the RH1 Binding
The two RH1 aziridinyl rings point away from the isoal-apo-QR1 structure, loop L9 of the C-terminal domain
lozaxine ring, allowing the quinone core of the drug tocloses the empty NAD adenosine site in all the com-
interact fully with rings A and B of the flavin; the 5-azi-plexes analyzed here.
ridinyl group stacks against Trp-105, and that at posi-
tion 2 (position numbering in Figure 1) rests above loopDrug Binding
L6 (Figure 2a). His-194 has to move from its position
Introduction
in the apo structure to accommodate this last group.
Aziridinyl substituents have been shown to increase the
Quinone oxygens O1 and O4 make hydrogen bonds with
potency and in vitro selectivity of quinolic drugs toward the His-161 N and the Tyr-128 OH (Table 2). The angle
QR1-rich cells under aerobic conditions [7]. The three between the planes of the drug and the isoallozaxine is
compounds examined in this study have in common a 15, departing from the exact aromatic ring stacking
1,4-benzoquinone core with an aziridinyl group at posi- observed in the rQR1 complexes with CB/DQ and
tion 5. In addition, the 6-methyl carbon and the 2-aziridi- NADP. The 5-aziridinyl nitrogen is the closest to the
nyl nitrogen of RH1 occupy the positions of the indo- FAD N5, the atom of reduced FAD that carries the hy-
lequinone C3 and N1, respectively. For comparison, we dride that is transferred to the drug. Provided there is
define this set of 13 atoms as the common pharmaco- no change in the orientation of the bound substrate
phore of the three drugs (shown in red in Figure 1). when the FAD is reduced, this atom will receive the
The binding of the prodrugs to QR1 buries between hydride during the reduction of RH1.
447 and 585 A˚2 of apolar accessible area of the protein ARH019 Binding
(total buried area between 591 and 740 A˚2). All three The ARH019 used was a mixture of both enantiomers
drugs bind with their benzoquinone rings in one side of of the methyl at position 2 of the aziridinyl group. The
the pocket, stacked between Tyr-128 and flavin rings experimental electron density of the 2-methyl-aziridinyl
A and B. Tyr-128 swings over the substrate, making shows a mixture of all four cases (two enantiomers and
van der Waals contacts with the aromatic core of the rotation around the aziridinyl-indole C5 bond), indicating
drugs (Figures 2a, 2b, and 2c). RH1 and ARH019, a that the enzyme does not select among these forms. As
benzoquinone and an indolequinone, bind to QR1 with is the case in RH1, the plane of the ARH019 indolequi-
similar spatial arrangements such that their pharmaco- none departs from an exact aromatic parallel stacking
phore atoms overlap with a low rmsd of only 0.6 A˚ (Figure with the FAD (plane-to-plane angle of 16; Table 2). The
4). Surprisingly, this is not the case with the two indo- methyl-aziridinyl group stacks against the Trp-105 in-
lequinones EO9 and ARH019. Although chemically dole. The 2-phenyl group points toward the outside of
highly similar (they differ only in their substituents at the active site pocket, stacking over Gly-149 and Gly-
positions 2 and 5), they bind to the enzyme in different 150 in L6 (Figure 2b). The structure of this complex
illustrates how the enzyme’s active site is capable oforientations.
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Figure 2. Stereo Views of Prodrug Molecules
Bound to hQR1
In all the Figures the 2Fo  Fc electronic den-
sity around each drug is displayed in cyan.
Secondary structure elements of monomers
A (green) and B (light blue) are shown. QR1
residues, the FAD, and the drug are drawn
using a stick model. Atoms are colored using
the following scheme: red for oxygen, blue
for nitrogen, gray for carbon, and yellow for
phosphorous. (a) shows RH1, (b) shows
ARH019, and (c) shows EO9.
accommodating a quinone with a large aromatic substit- tion. The other quinone oxygen atom, O4, is hydrogen
bonded to Tyr-126 OH. Indolequinone ring atom C6 isuent. This compound can serve as a model for other
drugs such as the antibiotic streptonigrin, another good the closest to the FAD N5. The electron density observed
for the 2-propenol tail is weak in some of the four equiva-substrate of the enzyme [16]. Quinone oxygens O7 and
O4 are hydrogen bonded to the His-161 N and the Tyr- lent sites, indicating that this group adopts multiple con-
formations in the binding site.126 OH. The 3-hydroxymethyl group further stabilizes
the binding by making a hydrogen bond to Tyr-128 OH.
EO9 Binding Relation between Drug Binding and Drug Reduction
Although the published information about the kineticsDespite their chemical similarity, EO9 binds in an orien-
tation opposite that of ARH019 (Figure 4); the positions of the reduction of these three drugs is incomplete, it
is clear that they are all better substrates for QR1 thanof the pharmacophoric atoms do not match those de-
scribed above. EO9 binding buries 176 A˚2 of polar area the widely used MC. Human QR1 reduces RH1 (Vmax
45.2  2 mol/min/mg) 6.5 times faster than EO9 (7.7 and 492 A˚2 of apolar area. Bound EO9 is more centered
over the FAD isoallozaxine, is closer to ring B, and re- 2 mol/min/mg) and 14 times faster than ARH019 (3.3
2 mol/min/mg) [7, 15, 16].sembles DQ in the hQR1-DQ complex. The drug’s plane
is almost parallel to the isoallozaxine rings (angle of 3.6  The reduction rates by QR1 of drugs similar to those
described above show a strong correlation with the0.8; Table 2) with its 5-aziridinyl group in the pocket
defined by Phe-106. The distance from O7 to the His- modes of binding suggested by the structures. Aziridi-
nylbenzoquinones (Figure 1) tolerate large substitutions161 N is 3.3 A˚, indicating a weak hydrogen bond interac-
Complexes of QR1 with Antitumor Prodrugs
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Figure 3. Changes in the Catalytic Site upon
Drug Binding
(a) Water-accessible molecular surface of the
apo enzyme. The surface of the pocket corre-
sponding to F232, Y128, W105, and F106 is
colored green (with the exception of the Y128
OH, which is red), the FAD is cyan, and the
small yellow patch indicates the position of
the hydride (at the FAD’s N5) to be transferred
in the two-electron reduction of the drug.
(b) Water-accessible molecular surface of the
drug bound form. In addition to the colors
used in (a), H161 is colored purple.
(c) Stick model of the active site residues in
the apo enzyme. The atoms are colored using
the color scheme of Figure 2.
(d) Stick model of the drug bound active site.
The atoms are colored using the color
scheme of Figure 2.
only at position 3 (X) or at position 6 (X). The RH1-QR1 homologs studied by Beall et al. [19]) illustrate the effect
of small differences in the substituents (X) at position 5complex shows that a substituent at one of these two
positions points to the outside of the pocket, while the (Figure 5). If one assigns to these compounds a putative
binding mode based on their homology with EO9 orother position can only accommodate small substitu-
ents which point to the inside. Thus, drugs with progres- ARH019 (Figure 5), analysis of the published data sug-
gests a correlation between the binding orientation andsively larger symmetrical substitutions have decreasing
rates of reduction [13]. In the case of indolequinones the rate of reduction by the enzyme. The normalized
reduction activities (Figure 5) of the members of set A(Figure 1), substituents (R) of different shapes and sizes
are generally well tolerated at position 2 [7, 21]. The (predicted to bind like EO9) and set B (predicted to bind
like ARH019) display a similar effect with the change ofindolequinone-QR1 complexes show that substituents
at this position point out of the binding pocket. A variety the substituent at position 5 (X-substituent). EO9 (com-
pound A2) has the highest reduction rate of the EO9-of small X substituents (position 5) are tolerated. At posi-
tion 3, small size substituents (R) have a small effect like compounds; compounds with slightly longer sub-
stituents such as E07 (A1) and EO8 (A3) are reduced aton the reduction rate, with electron-withdrawing groups
increasing the rate. Compounds with three substituents lower rates [7, 22]. Compound EO5A (A4), which has
the bulkiest X substituent, is not reduced by QR1. Inof the type CH2R (R  leaving group) inactivate the
enzyme [19]. contrast, compound B4 is a QR1 substrate, although
with a 10-fold reduction in rate. This indicates that theEO9 and ARH019 bind hQR1 in dissimilar ways, al-
though both are aziridinylindolequinones. The kinetics enzyme can accommodate bulky 5-substituents more
efficiently in compounds that bind like ARH019 (orienta-of reduction of a group of closely related compounds
(EO9 homologs studied by Bailey et al. [22] and ARH019 tion B) than in compounds that bind like EO9 (orientation
Figure 4. Stereo View of the Superposition of
the Three Drugs in the Catalytic Site
The drugs’ carbon atoms are colored pink for
RH1, green for ARH019, and light blue for
E09. The model of the protein of the complex
(RH1-hQR1) was used to represent the bind-
ing site.
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Table 2. Interactions between the Prodrugs and hQR1
Enzyme/FAD Atom RH1 Distance (A˚) E09 Distance (A˚) ARH019 Distance (A˚)
His 161 N O1 2.9  0.2 O4 3.3  0.2 O7 3.0  0.1
FAD N5 N5 3.5  0.3 C6 3.6  0.1 N5 3.8  0.2
C51 3.4  0.2 C5 3.8  0.05 C51 3.5  0.2
C5 4.4  0.3 O7 3.8  0.1
C4 4.8  0.3
O4 4.6  0.2
FAD N10 O4 3.5  0.3 N1 3.5  0.1 O4 3.3  0.1
Tyr-126 OH O7 2.9  0.1
Tyr-128 OH O4 3.3  0.2 N1 3.3  0.2 O31 2.5  0.3
Angle between planes (FAD/prodrug) 15.0  5 3.6  0.8 16.0  3.1
Angle between planes (178/prodrug) 8.5  4.5 13.5  2.7 27.7  5.7
A). In addition to these effects, the electronic character- the data of the RH1 parent compound MeDZQ, which
shows the typical 4-fold increase in rate from hQR1 toistics of the substituents also affect the reduction rates,
mainly by affecting the reduction potential of the com- rQR1. Interestingly, species differences have a greater
effect on EO9, which is reduced 27 times faster by rQR1pounds [19].
Sequence identities among the three species for than by hQR1. The binding position of EO9, which is
closer to the center of the active site than the otherwhich QR1 structural data is available are 86% for rat
and human, 93% for mouse and rat, and 86% for human compounds are, apparently makes the drug more sus-
ceptible to the change in the FAD position.and mouse. Most natural substrates (e.g., menadione)
are reduced two to four times faster by the rat than by Mouse QR1 (mQR1), although more similar in overall
sequence to rQR1 than to hQR1, contains the key resi-the human enzyme [5, 23]. The Kms of rQR1 for EO9 and
MeDZQ (RH1’s parent drug) are 2-fold lower than those dues Ala-130 and Gln-104 found in the human sequence.
In agreement with the discussion above, the kinetics ofof the human enzyme, with a Vmax range 2–3 times larger
[16]. mQR1, whose structure [4] and kinetic profile re- hQR1 reactions is more similar to that of mQR1 than to
that of rQR1. Thus, mouse would be a better experimen-semble those of hQR1 [5], has been shown to have Kms
for RH1 and EO9 in the order of 105 M. Only a few tal system for testing QR1-activated prodrugs than rat,
which is the animal model currently used.differences between the enzymes from rats and humans
have a direct effect on the catalytic site and can provide
a rationale for the differences in catalytic efficiency. For Mechanism of Drug Reduction
As was observed in hQR1-DQ and rQR1/CB-DQ, theexample, the Thr/Ala-130 and Tyr/Gln-104 (rat/human)
differences result in the largest change in the structure quinone ring carbon atoms seem to be in the best posi-
tions to accept the hydride from FADH2 (Table 2). Inof the active site [4]: a tilt of the FAD isoallozaxine ring
such that ring C in the human enzyme sits 0.5 A˚ deeper all three complexes reported here, one of the quinone
oxygens interacts closely with the His-161 N (distancein the active site than it does in the rat enzyme [4].
As kinetic data are not available for RH1 and ARH019 3.0–3.3 A˚). Since the quinone oxygen can only partici-
pate in a hydrogen bond as a proton acceptor, the His-reduction by rQR1, it is only possible to extrapolate from
Figure 5. Reduction of Antitumor Prodrugs
Top panel: Nomenclature and the depen-
dence of the reduction rate with small varia-
tions in size of the X substituent in indolequi-
nones related to E09 and ARH019. The
reduction rates are normalized to the rate of
the methylaziridinyl (3) substituted com-
pound of each subfamily.
Bottom panel: Scheme of the two putative
modes of binding for each subfamily.
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Catalytic Site Changes upon Drug Binding
The structural changes associated with substrate bind-
ing occur at one side of the binding pocket (Figure 3) and
involve only a few residues located above isoallozaxine
rings A and B. Phe-106, Tyr-128, and Phe-232 show
the largest displacements with respect to the apo-hQR1
structures reported earlier [4].
In the case of the binding of DQ, RH1, and ARH019,Figure 6. Resonance of the Azirididinyl Benzoquinone
the movement of the Phe-106 side chain controls theThis resonance is suggested as the form that accepts the hydride
from the FADH2. The negative charge at the quinolic oxygen is stabi- accessibility to the pocket defined by Phe-106 itself,
lized by a hydrogen bond to the positively charged H161. Trp-105, Phe-178, and the main chain of Ile-175. Phe-
106 rotates from its position in apo-hQR1 so as to in-
crease the pocket complementarity to the substrates.
161 imidazole must be protonated at N when the qui- When EO9 binds to hQR1, the pocket opens to make
nones are bound to QR1. In the proposed mechanism room for the group at position 5. The side chain of Tyr-
[3], FADH2 is in the enolic form. O2F captures the proton 128 has the largest freedom of movement in the active
from Tyr-155, thereby generating a negative charge (ty- site, being constrained only by Phe-232. In rQR1/CB-
rosinate anion) for which the nearby His-161 compen- DQ and rQR1/NADP, Tyr-128 occupies similar posi-
sates either by a proton transfer or simply by becoming tions and interacts either with the nicotinamide (in the
positively charged. Of these two possibilities, charge rQR1-NADP complex), or with the CB triazine ring and
compensation is the most likely, because a direct proton DQ (in the rQR1/CB-DQ) [3]. In the structures of apo-
transfer from the imidazole to Tyr-155 would have to mQR1 and apo-hQR1, this tyrosine swings back into the
take place across a long distance (4.0 A˚) and with an catalytic site and, together with Phe-232, closes the
unfavorable angle. Therefore, release of NAD(P) from NAD(P) binding site [4]. This seems to be the preferred
the reduced enzyme must be accompanied by proton- conformation when there are no molecules occupying
ation of the N of His-161 to produce a positively the region just over ring A, and this conformation pro-
charged imidazole. Analysis of the hydrogen bonding tects this side of the binding site from the solvent. In
pattern of QR1 structures indicates that the N of His- the hQR1-DQ complex, Tyr-128 binds DQ through a
161 is hydrogen bonded to the OH of Tyr-132 (2.8 A˚), water molecule. Nevertheless, in all three complexes
which in turn binds to a well-conserved chain of hydro- reported in this paper, Tyr-128 is present in a conformer
gen bonded atoms, many of them structural water mole- that more closely resembles that observed in the ternary
cules. This proton wire connects to the bulk solvent and complex rQR1/CB-DQ than that in apo-(h/m)QR1 or
can easily shuttle protons in and out to change the hQR1-DQ.
protonation state of His-161 during catalysis. Other residues also contribute to the binding of these
During reduction of the substrate, the hydride is trans- drugs. Trp-105 and Phe-106 participate by forming a
ferred from the FADH2 to the quinone, and the charge hydrophobic pocket where one of the substrate’s 5-azi-
reorganizes. Tyr-155 reprotonates and the N proton ridinyl groups docks. Residues Gly-149, Gly-150 (in L6),
of His-161 is transferred to the reduced quinone. After and His-194 form a pocket in one side of the mouth of
release of the reduced quinone, solvent molecules can the catalytic site. They provide van der Waals contacts
permeate the catalytic site and protonate the His-161 with substituents at position 2 of the quinone ring such
N, while N loses its proton via Tyr-132. This step is as the aziridinyl of RH1, the phenyl of ARH019, and
driven by the higher basicity of N (pKa difference is 0.6 (partially) the propenol chain of EO9.
units for free histidine). In summary, all these complexes
seem to indicate that His-161 has two roles in the cata-
lytic cycle: it compensates the charge in Tyr-155 after Biological Implications
flavin reduction and NAD(P) release, and it provides a
proton to the quinone oxygen during hydride transfer, QR1 is an inducible cytosolic enzyme that protects the
organism against the deleterious effects of quinonesi.e., it is the proton donor required for the overall reaction
FADH2  quinone  H ↔ FAD  hydroquinone. and other electrophiles. Paradoxically, the same two-
electron reaction that inactivates quinones can activateOne remaining question is the nature of the atom that
receives the hydride from the reduced flavin. In the cases certain chemotherapeutic prodrugs, thereby rendering
them cytotoxic. Two additional properties of QR1 makeof RH1 and ARH019, the nitrogen of the aziridinyl group
is best located for accepting the hydride (Table 2). In this enzyme an ideal target for the development of anti-
tumor compounds activatable by two-electron reduc-general, the aziridinyl nitrogen would not be a good
hydride acceptor. However, in the case of aziridinyl qui- tions. First, QR1 is inducible in normal tissues. Second,
the enzyme is constitutively expressed in some impor-nones, the resonance shown in Figure 6 can render
this atom a better hydride acceptor. His-161 is ideally tant tumors such as non-small-cell lung, breast, pancre-
atic, colorectal, and gastric cancers. A large number oflocated to stabilize this resonance form by donating a
proton to the negatively charged oxygen. The existence QR1-directed compounds have been synthesized and
tested, but no structural information on their interactionof this resonance form is supported by the experimental
electron density that shows that the nitrogen of the aziri- with QR1 has been available. The three structures of
complexes of QR1 with chemotherapeutic prodrugs re-dinyl group is more planar that what can be expected
for an sp3 hybridization. ported here provide evidence for two important charac-
Structure
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tions we are reporting are the only ones that produce featurelessteristics of QR1-drug binding: first, QR1 modifies the
Fo  Fc difference maps after refinement. All other orientations re-shape of its binding site to accommodate different com-
sulted in difference maps with significant positive and negative fea-pounds, and second, compounds of similar structure
tures that suggested changes leading to the reported orientations.
may bind to QR1 in different orientations. The ability In addition, the reported orientations showed the best chemical
to accommodate different compounds is accomplished interactions with active site residues. A torsional molecular dynam-
ics refinement, either at constant temperature (2000 K) or as a slow-primarily by movements of the side chains of two resi-
cooling annealing, was followed by energy minimization, restraineddues: Tyr-128 of one monomer moves to accommodate
B factor refinement, and manual rebuilding in SIGMAA-weightedthe main ring of the drugs, and Phe-106 of the other
maps with the program O [29]. Figures were drawn with the pro-monomer moves to accommodate the 5-aziridinyl
grams MOLSCRIPT [30], BOBSCRIPT [31], and RASTER3D [32].
group. The structures also suggest that because of its Structure quality was assessed with the program PROCHECK, which
interaction with the pocket defined by loop L6, the sub- is part of the CCP4 suite of programs [33]. Molecular surfaces were
drawn with the program GRASP [34]. Solvent accessible surfacestituent at position 2 plays an important role in drug
areas (ASA) were calculated with the program NACCESS [35].binding, particularly in its size, flexibility, and hydropho-
bic character. As a result of these requirements, com-
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